NCT01637467

Brief Summary

Electrical muscle stimulation (EMS) is the therapy used to passively activate muscles using electrodes on the surface of the skin. EMS may be helpful in preserving muscle function in people who are on bedrest due to critical illness in the intensive care unit. The purpose of this study is to determine the safety and feasibility of implementing EMS in critically ill patients who are on mechanical ventilation for greater than 7 days, and examine the effects of 4 weeks of EMS on leg muscle size, muscle strength and functional outcomes in these patients. The investigators hypothesize that EMS will be safe and feasible and that critically ill patients receiving EMS will show a smaller loss of muscle size and strength than those in the control group, who do not receive EMS.

Trial Health

87
On Track

Trial Health Score

Automated assessment based on enrollment pace, timeline, and geographic reach

Enrollment
30

participants targeted

Target at P25-P50 for phase_1

Timeline
Completed

Started Jul 2012

Typical duration for phase_1

Geographic Reach
1 country

1 active site

Status
completed

Health score is calculated from publicly available data and should be used for screening purposes only.

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Key milestones and dates

Study Start

First participant enrolled

July 1, 2012

Completed
5 days until next milestone

First Submitted

Initial submission to the registry

July 6, 2012

Completed
5 days until next milestone

First Posted

Study publicly available on registry

July 11, 2012

Completed
3.2 years until next milestone

Primary Completion

Last participant's last visit for primary outcome

October 1, 2015

Completed
Same day until next milestone

Study Completion

Last participant's last visit for all outcomes

October 1, 2015

Completed
Last Updated

February 9, 2016

Status Verified

May 1, 2015

Enrollment Period

3.3 years

First QC Date

July 6, 2012

Last Update Submit

February 5, 2016

Conditions

Keywords

critical illnessmyopathyelectrical muscle stimulation

Outcome Measures

Primary Outcomes (1)

  • feasibility of EMS treatment

    the number of EMS treatments that are successfully applied will be expressed as a frequency of the total number of treatments attempted

    4 weeks

Secondary Outcomes (2)

  • muscle strength

    baseline, 2 weeks and 4 weeks

  • muscle thickness

    baseline, 2 weeks, 4 weeks

Study Arms (2)

EMS intervention

EXPERIMENTAL

The experimental group will received EMS at a therapeutic level.

Other: Electrical muscle stimulation (EMS)

Sham

SHAM COMPARATOR

The sham group will receive EMS at a sub-therapeutic level.

Other: Sham EMS

Interventions

EMS delivered to the quadriceps and gluteal muscles, twice daily, 30 minutes per session for up to 4 weeks.

EMS intervention

Sham EMS delivered to the quadriceps and gluteal muscles, twice daily, 30 minutes per session for up to 4 weeks.

Sham

Eligibility Criteria

Age18 Years+
Sexall
Healthy VolunteersNo
Age GroupsAdult (18-64), Older Adult (65+)

You may qualify if:

  • admitted to the medical-surgical ICU or cardiovascular ICU
  • walking independently prior to admission
  • mechanically ventilated for more than 7 days (i.e. prolonged ventilation)
  • receiving enteral or parenteral nutrition.

You may not qualify if:

  • history of neurological or psychiatric disease
  • primary muscle disease (e.g. muscular dystrophy, polymyositis)
  • catastrophic neurological event
  • receiving palliative care
  • contraindications to EMS (e.g. cardiac pacemaker/defibrillator, pregnancy, infected or cancerous lesions in proximity of electrode sites)
  • inadequate access to electrode sites due to medical devices
  • lower extremity edema affecting the thighs or buttocks
  • BMI \> 35 kg/m2
  • allergies to adhesives or latex

Contact the study team to confirm eligibility.

Sponsors & Collaborators

Study Sites (1)

Toronto General Hospital

Toronto, Ontario, M5G 2C4, Canada

Location

MeSH Terms

Conditions

Critical IllnessMuscular Diseases

Condition Hierarchy (Ancestors)

Disease AttributesPathologic ProcessesPathological Conditions, Signs and SymptomsMusculoskeletal DiseasesNeuromuscular DiseasesNervous System Diseases

Study Officials

  • Vincent Lo, BSc(PT)

    University Health Network, Toronto

    PRINCIPAL INVESTIGATOR
  • Sunita Mathur, PhD

    University of Toronto

    PRINCIPAL INVESTIGATOR

Study Design

Study Type
interventional
Phase
phase 1
Allocation
RANDOMIZED
Masking
TRIPLE
Who Masked
PARTICIPANT, INVESTIGATOR, OUTCOMES ASSESSOR
Purpose
TREATMENT
Intervention Model
PARALLEL
Sponsor Type
OTHER
Responsible Party
PRINCIPAL INVESTIGATOR
PI Title
Principal Investigator

Study Record Dates

First Submitted

July 6, 2012

First Posted

July 11, 2012

Study Start

July 1, 2012

Primary Completion

October 1, 2015

Study Completion

October 1, 2015

Last Updated

February 9, 2016

Record last verified: 2015-05

Locations